Patient Square Capital LP Acquires New Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Patient Square Capital LP bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,361,979 shares of the company's stock, valued at approximately $10,882,000. EyePoint Pharmaceuticals comprises 4.0% of Patient Square Capital LP's holdings, making the stock its 5th largest holding. Patient Square Capital LP owned 2.54% of EyePoint Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of EYPT. Charles Schwab Investment Management Inc. increased its position in EyePoint Pharmaceuticals by 5.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company's stock worth $1,141,000 after purchasing an additional 7,967 shares during the last quarter. Intech Investment Management LLC acquired a new stake in EyePoint Pharmaceuticals during the third quarter worth about $136,000. GSA Capital Partners LLP increased its position in EyePoint Pharmaceuticals by 129.6% during the third quarter. GSA Capital Partners LLP now owns 32,979 shares of the company's stock worth $264,000 after purchasing an additional 18,616 shares during the last quarter. Greenwich Wealth Management LLC increased its position in EyePoint Pharmaceuticals by 8.3% during the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company's stock worth $93,000 after purchasing an additional 900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock worth $82,000 after purchasing an additional 4,172 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EYPT has been the subject of several research analyst reports. JPMorgan Chase & Co. lowered their target price on shares of EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating for the company in a research note on Tuesday, August 13th. HC Wainwright lowered their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, November 11th. StockNews.com raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Saturday, September 21st. Robert W. Baird lowered their price objective on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating for the company in a research note on Monday, November 11th. Finally, Chardan Capital raised their price objective on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat.com, EyePoint Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $28.00.

EyePoint Pharmaceuticals Stock Up 1.6 %

EyePoint Pharmaceuticals stock traded up $0.13 during trading on Wednesday, reaching $8.49. The stock had a trading volume of 647,361 shares, compared to its average volume of 940,025. EyePoint Pharmaceuticals, Inc. has a 52-week low of $7.40 and a 52-week high of $30.99. The business has a 50 day moving average price of $9.79 and a 200 day moving average price of $9.35. The stock has a market cap of $579.44 million, a PE ratio of -4.18 and a beta of 1.45.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.